Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation

• Main Authors: M. V. Zhuravleva (Author), K. A. Kokushkin (Author), E. A. Luchinin (Author), E. V. Luchinina (Author), T. R. Kameneva (Author), E. V. Kuznetsova (Author), V. S. Krysanova (Author), E. V. Makarova (Author), L. G. Zhukova (Author)
• Formato: Livro
• Publicado em: IRBIS LLC, 2024-02-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant "docetaxel / carboplatin / trastuzumab + pertuzumab&q...